Back in November 2012 we invested in Maxygen (MAXY) based on a simple premise. The company was in the process of liquidating and returning capital to the shareholders, and had no ongoing operations. Since they had more cash sitting on the books than the market value of the company, some return was guaranteed. Without any [...]
MAXY – Maxygen, Inc.
Maxygen, Inc., a biopharmaceutical company, engages in developing various products in the field of human therapeutics in North America. It focuses on the development of MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.
Maxygen (MAXY) historically has been a biotech company engaged in discovery and development of protein pharmaceuticals for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. For the last several years, the company has stopped its operations completely and is actively trying to monetize its R&D assets and return value to the shareholders. As of [...]
4 Extreme Value Stocks for Your Portfolio Choose your own metrics and run these stocks through your own diligence process. You will find that these stocks tick most of the boxes for undervaluation. This is one of the most stringent screens I run, with the following filters P/E below 10 P/B below 1 Cash/Price > [...]
Cash and cash equivalents are the easiest balance sheet line items to value. Typically they can be valued at 100 cents on a dollar. The holy grail of value investing is of course, finding stocks that carry more cash on their books than the entire company is worth in the stock market. And if the [...]